Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03732352
Recruitment Status : Recruiting
First Posted : November 6, 2018
Last Update Posted : November 12, 2019
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Translational Research in Oncology
AstraZeneca
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 1, 2020
Estimated Study Completion Date : November 1, 2021